Clinical trials
Colorectal Neoplasms trials in Japan
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
170 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 2 |
| 2006 | 6 |
| 2007 | 7 |
| 2008 | 13 |
| 2009 | 4 |
| 2010 | 2 |
| 2011 | 3 |
| 2012 | 3 |
| 2013 | 8 |
| 2014 | 3 |
| 2015 | 7 |
| 2016 | 6 |
| 2017 | 3 |
| 2018 | 4 |
| 2019 | 11 |
| 2020 | 12 |
| 2021 | 14 |
| 2022 | 12 |
| 2023 | 6 |
| 2024 | 16 |
| 2025 | 15 |
| 2026 | 7 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 72 |
| Recruiting | 37 |
| Active, not recruiting | 29 |
| Terminated | 20 |
| Unknown status | 11 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pfizer | 16 |
| Novartis Pharmaceuticals | 10 |
| Eli Lilly and Company | 9 |
| AbbVie | 7 |
| Taiho Pharmaceutical Co., Ltd. | 7 |
| AstraZeneca | 6 |
| Bayer | 6 |
| Amgen | 5 |
| Hokkaido Gastrointestinal Cancer Study Group | 5 |
| Takeda | 5 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Colorectal Neoplasms | 170 |
| Carcinoma, Non-Small-Cell Lung | 29 |
| Neoplasms | 22 |
| Colonic Neoplasms | 21 |
| Neoplasm Metastasis | 18 |
| Endometrial Neoplasms | 14 |
| Stomach Neoplasms | 14 |
| Breast Neoplasms | 13 |
| Rectal Neoplasms | 13 |
| Ovarian Neoplasms | 12 |
Trials
Showing 76 to 100 of 170. Each trial links to its page on Pharma Observatory.
70 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.